

THERAPEUTICS FOR 'SILENT' CANCERS



PHM169A
February 2015

Paul Evers
Project Analyst

ISBN: 1-62296-045-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
MARKET ANALYSES AND FORECASTS	2
METHODOLOGY	3
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET SHARE FOR (%)</i>	7
CHAPTER 3 OVERVIEW	11
CANCER: A GLOBAL PERSPECTIVE	11
GROWING PROBLEM	11
MARKET DYNAMICS	12
SOME LEADING ANTICANCER DRUGS	12
DRUG CATEGORIES	12
ASYMPTOMATIC CANCER	15
TELLTALE GENES	16
TUMOR MARKERS	16
CHAPTER 4 BRAIN CANCER	19
CAUSE, FREQUENCY AND COURSE	19
DIAGNOSIS	19
IMAGING TESTS	20
MRI	20
CT Scan	21
PET Scan	21
Cerebral Arteriogram	21
Lumbar Puncture or Spinal Tap	22
Myelogram	22
Tissue Sampling/Biopsy/Surgical Removal of a Tumor	22
PROGNOSIS	22
TREATMENT	22
RADIATION THERAPY AND NEUROTOXICITY	23
CHEMOTHERAPY	23
NEW DEVELOPMENTS IN RESEARCH	24
<i>TABLE 1 COMPOUNDS IN CLINICAL DEVELOPMENT FOR BRAIN CANCER</i>	24
RECENT RESEARCH REPORTS	26

TOPIC	PAGE NO.
MARKET	27
<i>TABLE 2 GLOBAL AND U.S. BRAIN CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	28
<i>TABLE 3 BRAIN CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	28
<i>TABLE 4 BRAIN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	28
CHAPTER 5 CANCER OF THE MOUTH AND LARYNX	30
CAUSE, FREQUENCY AND COURSE	30
DIAGNOSIS	30
TREATMENT	31
LARYNGEAL CANCER	31
CAUSE, FREQUENCY AND COURSE	31
DIAGNOSIS	32
TREATMENT	32
NEW RESEARCH DEVELOPMENTS	32
<i>TABLE 5 COMPOUNDS IN CLINICAL DEVELOPMENT FOR HEAD AND NECK CANCER</i>	33
LYMPHOSEEK	33
REOLYSIN	34
MULTIKINE	34
MARKET	35
<i>TABLE 6 GLOBAL AND U.S. MOUTH AND LARYNX CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	35
<i>TABLE 7 MOUTH AND LARYNX CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	35
<i>TABLE 8 CANCER OF MOUTH AND LARYNX FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	36
CHAPTER 6 CANCER OF THE ESOPHAGUS	38
CAUSE, FREQUENCY AND COURSE	38
DIAGNOSIS	38
TREATMENT	39
NEW RESEARCH DEVELOPMENTS	40
GENETICS	40
SCREENING AND PREVENTION	40
SURGERY	40
CHEMOTHERAPY	41
TARGETED DRUGS	41
<i>TABLE 9 COMPOUNDS IN CLINICAL DEVELOPMENT FOR ESOPHAGEAL CANCER</i>	41
MARKET	42
<i>TABLE 10 GLOBAL AND U.S. ESOPHAGEAL CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	42
<i>TABLE 11 ESOPHAGEAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	42
<i>TABLE 12 ESOPHAGEAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	43
CHAPTER 7 LIVER CANCER	45
CAUSE, FREQUENCY AND COURSE	45

TOPIC	PAGE NO.
DIAGNOSIS	45
TREATMENT	46
OTHER PRIMARY LIVER CANCERS	46
METASTASES	47
NEW RESEARCH DEVELOPMENTS	47
VIRUS THERAPY	48
<i>TABLE 13 LIVER CANCER: NEW DEVELOPMENTS IN RESEARCH</i>	49
MARKET	50
<i>TABLE 14 GLOBAL AND U.S. LIVER CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	50
<i>TABLE 15 LIVER CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>TABLE 16 LIVER CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	51
CHAPTER 8 RENAL CANCER	53
CAUSE, FREQUENCY AND COURSE	53
DIAGNOSIS	53
TREATMENT	54
NEW RESEARCH DEVELOPMENTS	56
GENETICS	56
NEW APPROACHES TO LOCAL TREATMENT	56
TARGETED THERAPIES	56
IMMUNOTHERAPY	56
VACCINES	57
BONE MARROW OR STEM CELL TRANSPLANT	57
<i>TABLE 17 RENAL CANCER: NEW RESEARCH DEVELOPMENTS</i>	58
MARKET	59
<i>TABLE 18 GLOBAL AND U.S. RENAL CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	60
<i>TABLE 19 RENAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	60
<i>TABLE 20 RENAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	60
CHAPTER 9 CANCER OF THE PANCREAS	62
CAUSE, FREQUENCY AND COURSE	62
DIAGNOSIS	62
TREATMENT	63
NEW RESEARCH DEVELOPMENTS	64
<i>TABLE 21 PANCREATIC CANCER: NEW RESEARCH DEVELOPMENTS</i>	67
MARKET	69
<i>TABLE 22 GLOBAL AND U.S. PANCREATIC CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	69
<i>TABLE 23 PANCREATIC CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	70
<i>TABLE 24 PANCREATIC CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	70
CHAPTER 10 CANCER OF THE CERVIX	72
CAUSE, FREQUENCY AND COURSE	72

TOPIC	PAGE NO.
DIAGNOSIS	73
TREATMENT	73
PREVENTION: VACCINES	73
TREATMENT	74
Cisplatin	74
Ifosfamide (Ifex)	74
Fluorouracil (Adrucil)	75
Paclitaxel (Taxol)	75
Topotecan (Hycamtin)	75
Docetaxel	75
Gemcitabine	75
Vaccines: Inactivated, Viral	75
Human Papillomavirus Vaccine, Quadrivalent (Gardasil)	75
Human Papillomavirus Vaccine, Bivalent (Cervarix)	76
Targeted Drug Therapy	76
NEW RESEARCH DEVELOPMENTS	76
IXEMPRA	76
ISA101 VACCINE	77
VELIPARIB	77
OLAPARIB	77
Avastin	77
<i>TABLE 25 NEW RESEARCH DEVELOPMENTS IN CERVICAL CANCER</i>	77
MARKET	78
<i>TABLE 26 GLOBAL AND U.S. CERVICAL CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	79
<i>TABLE 27 CERVICAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	79
<i>TABLE 28 CERVICAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	80
CHAPTER 11 OVARIAN CANCER	82
CAUSE, FREQUENCY AND COURSE	82
DIAGNOSIS	82
TREATMENT	83
PACLITAXEL	83
CARBOPLATIN	84
DOXIL	84
TAXOTERE/DOCETAXEL	84
CISPLATIN	84
GEMZAR	85
HYCAMTIN	85
NAVELBINE	85
CARBOPLATIN	85
OVARIAN CANCER SCREENING	85
CA125 BLOOD TEST	85
TRANSVAGINAL ULTRASOUND	86
NEW DEVELOPMENTS IN TREATMENT	86
RISK FACTORS AND CAUSES	86

TOPIC	PAGE NO.
PREVENTION	86
DIAGNOSIS	87
TREATMENT	87
Chemotherapy	87
Targeted Therapy	87
Immunotherapy	88
ASCO 2013	88
Asco 2014	90
Other Developments	91
<i>TABLE 29 NEW DEVELOPMENTS IN OVARIAN CANCER RESEARCH</i>	94
MARKET	96
<i>TABLE 30 GLOBAL AND U.S. OVARIAN CANCER MARKET, THROUGH 2019 (\$ MILLIONS)</i>	97
<i>TABLE 31 OVARIAN CANCER MARKET, FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)</i>	97
<i>TABLE 32 OVARIAN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)</i>	98
CHAPTER 12 TUMOR MARKERS	100
SCREENING AND EARLY DETECTION	100
DIAGNOSING CANCER	100
MONITORING	101
LOOKING FOR RECURRENCE	101
Tumor Markers Found in Blood or Urine	101
Alpha-fetoprotein (AFP)	101
BCR-ABL	101
Beta-2-microglobulin (B2M)	102
Beta-HCG	102
Bladder Tumor Antigen (BTA)	102
CA 15-3	102
CA 19-9	102
CA 27-29	102
CA 125	103
Calcitonin	103
Carcinoembryonic Antigen (CEA)	103
Chromogranin A	104
HE-4	104
Human Chorionic Gonadotropin (HCG)	104
Immunoglobulins	104
Free Light Chains	105
Inhibin	105
Neuron-specific Enolase (NSE)	105
NMP22	105
Prostate-specific Antigen (PSA)	105
Prostatic Acid Phosphatase (PAP)	106
S-100	106
Soluble Mesothelin-Related Peptides (SMRP)	106
Thyroglobulin	106

TOPIC	PAGE NO.
TUMOR MARKERS FOUND ON THE CANCER ITSELF	106
ANAPLASTIC LYMPHOMA KINASE (ALK)	107
BRAF	107
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)	107
HER2 (OR HER2/NEU, ERBB-2, OR EGFR2)	107
HORMONE RECEPTORS	108
KRAS	108
S-100	108
NEW DIRECTIONS IN TUMOR MARKER RESEARCH	108
GENOMICS	109
PROTEOMICS	109
CHAPTER 13 COMPANY PROFILES	111
ABBOTT LABORATORIES	111
ADVAXIS	111
AMGEN	111
APP PHARMACEUTICALS	112
ASTRAZENECA	112
BAYER	113
BIONUMERIK PHARMACEUTICALS	113
BOEHRINGER INGELHEIM GMBH	114
BRISTOL-MYERS SQUIBB	114
CELL THERAPEUTICS INC.	115
CHUGAI PHARMACEUTICAL	115
CLOVIS ONCOLOGY	115
DENDREON CORP.	116
DIGENE CORP.	116
EISAI INC.	116
ELI LILLY AND COMPANY	117
ENDOCYTE	117
FUJIREBIO DIAGNOSTICS	118
GE HEALTHCARE	118
GENENTECH	119
GLAXOSMITHKLINE	119
ISA PHARMACEUTICALS	120
JOHNSON & JOHNSON	120
LPATH	121
MERCK	121
MYRIAD GENETICS	122
NOVOCURE	122
OASMIA PHARMACEUTICAL	123
ONCOLYTICS	123
OXIGENE	124
PFIZER	124
PROVISTA DIAGNOSTICS	125
QIAGEN	125
QUEST DIAGNOSTICS	125

TOPIC	PAGE NO.
RADIANT PHARMACEUTICALS	126
ROCHE DIAGNOSTICS	126
SANOFI	127
TELIK INC.	127
TEVA PHARMACEUTICAL INDUSTRIES LTD.	128
ZILICO	128
CHAPTER 14 APPENDIX 1: GLOSSARY	130

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 COMPOUNDS IN CLINICAL DEVELOPMENT FOR BRAIN CANCER	24
TABLE 2 GLOBAL AND U.S. BRAIN CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	28
TABLE 3 BRAIN CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	28
TABLE 4 BRAIN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	28
TABLE 5 COMPOUNDS IN CLINICAL DEVELOPMENT FOR HEAD AND NECK CANCER	33
TABLE 6 GLOBAL AND U.S. MOUTH AND LARYNX CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	35
TABLE 7 MOUTH AND LARYNX CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	35
TABLE 8 CANCER OF MOUTH AND LARYNX FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	36
TABLE 9 COMPOUNDS IN CLINICAL DEVELOPMENT FOR ESOPHAGEAL CANCER	41
TABLE 10 GLOBAL AND U.S. ESOPHAGEAL CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	42
TABLE 11 ESOPHAGEAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	42
TABLE 12 ESOPHAGEAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	43
TABLE 13 LIVER CANCER: NEW DEVELOPMENTS IN RESEARCH	49
TABLE 14 GLOBAL AND U.S. LIVER CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	50
TABLE 15 LIVER CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	51
TABLE 16 LIVER CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	51
TABLE 17 RENAL CANCER: NEW RESEARCH DEVELOPMENTS	58
TABLE 18 GLOBAL AND U.S. RENAL CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	60
TABLE 19 RENAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	60
TABLE 20 RENAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	60
TABLE 21 PANCREATIC CANCER: NEW RESEARCH DEVELOPMENTS	67
TABLE 22 GLOBAL AND U.S. PANCREATIC CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	69
TABLE 23 PANCREATIC CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	70
TABLE 24 PANCREATIC CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	70
TABLE 25 NEW RESEARCH DEVELOPMENTS IN CERVICAL CANCER	77
TABLE 26 GLOBAL AND U.S. CERVICAL CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	79
TABLE 27 CERVICAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	79
TABLE 28 CERVICAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	80
TABLE 29 NEW DEVELOPMENTS IN OVARIAN CANCER RESEARCH	94

TABLE HEADING	PAGE NO.
TABLE 30 GLOBAL AND U.S. OVARIAN CANCER MARKET, THROUGH 2019 (\$ MILLIONS)	97
TABLE 31 OVARIAN CANCER MARKET, FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 (\$ MILLIONS)	97
TABLE 32 OVARIAN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 (\$ MILLIONS)	98

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET SHARE FOR (%)	7